- Home
- KRON vs AVTX Comparison
KRON vs AVTX Comparison
Compare KRON & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRON
- AVTX
- Stock Information
- Founded
- KRON 2017
- AVTX 2011
- Country
- KRON United States
- AVTX United States
- Employees
- KRON N/A
- AVTX N/A
- Industry
- KRON Medicinal Chemicals and Botanical Products
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- KRON Health Care
- AVTX Health Care
- Exchange
- KRON Nasdaq
- AVTX Nasdaq
- Market Cap
- KRON 54.4M
- AVTX 57.4M
- IPO Year
- KRON 2020
- AVTX 2015
- Fundamental
- Price
- KRON $0.72
- AVTX $4.25
- Analyst Decision
- KRON Buy
- AVTX Strong Buy
- Analyst Count
- KRON 3
- AVTX 6
- Target Price
- KRON $1.63
- AVTX $34.20
- AVG Volume (30 Days)
- KRON 790.8K
- AVTX 66.4K
- Earning Date
- KRON 05-20-2025
- AVTX 05-20-2025
- Dividend Yield
- KRON N/A
- AVTX N/A
- EPS Growth
- KRON N/A
- AVTX N/A
- EPS
- KRON N/A
- AVTX N/A
- Revenue
- KRON $9,848,000.00
- AVTX $441,000.00
- Revenue This Year
- KRON N/A
- AVTX N/A
- Revenue Next Year
- KRON N/A
- AVTX N/A
- P/E Ratio
- KRON N/A
- AVTX N/A
- Revenue Growth
- KRON 56.62
- AVTX N/A
- 52 Week Low
- KRON $0.67
- AVTX $4.15
- 52 Week High
- KRON $1.60
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- KRON 35.81
- AVTX 31.02
- Support Level
- KRON $0.67
- AVTX $4.80
- Resistance Level
- KRON $0.76
- AVTX $5.26
- Average True Range (ATR)
- KRON 0.05
- AVTX 0.45
- MACD
- KRON -0.01
- AVTX 0.03
- Stochastic Oscillator
- KRON 19.69
- AVTX 11.96
About KRON Kronos Bio Inc.
Kronos Bio Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of small molecule therapeutics to address deregulated transcription, a hallmark of cancer and autoimmune diseases.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).